Company of the Year: Novartis A diversified and successful business base, world-leading generics division, impressive drug pipeline, and strong financial performances helped earn Novartis the title of Company of the Year. By Steven Niles
Annual Report: Tough times for big pharma The top pharmaceutical companies are putting more resources into biotech as safety pressures, public scrutiny, and generic erosion increase. By Christiane Truelove
Abbott Abbott’s efforts to build its pharmaceutical, device, and nutritionals segments paid off with growth in each segment in 2007. By Joshua Slatko
AstraZeneca As AstraZeneca continues to improve the efficiency and effectiveness of operations by becoming leaner, the company underwent additional workforce reductions during 2007. By Steven Niles
Bayer Bayer continues to bolster its product portfolio and pipeline as the company makes financial strides. By Gina-Louise Monari
Biotechnology companies The biotechnology sector is facing many of the same setbacks as the overall healthcare industry, and is taking the necessary steps to endure. By Gina-Louise Monari
Bristol-Myers Squibb Bristol-Myers Squibb took a big step toward moving beyond the Plavix fiasco with a strong year in 2007. By Joshua Slatko
Generic companies Generic drug companies bit an even larger chunk out of the pharmaceutical pie in 2007. By Joshua Slatko
GlaxoSmithKline Under new leadership, GlaxoSmithKline is revamping business goals and strategies to move toward a stable and more profitable future. By Gina-Louise Monari
Japanese companies Government price reductions and an influx of foreign competition are putting the squeeze on domestic market share. By Steven Niles
Johnson & Johnson Faced with generic competition and challenges in the drug-eluting stent market, J&J took on restructuring initiatives in 2007 designed to improve cost structure. By Steven Niles
Lilly 2007 was a busy year for Eli Lilly, and the pace is showing no signs of slowing. By Joshua Slatko
Merck & Co. Three new superstars in their first full year on the market helped give Merck its largest sales jump of the decade. By Joshua Slatko
Merck KGaA The integration of Merck Serono represents a new era of growth at the company driven by biopharmaceuticals. By Gina-Louise Monari
Pfizer A struggling Pfizer found satisfaction with level sales as the company works its way through cost-cutting initiatives and loss of exclusivity for key products. By Steven Niles
Roche As Roche continues to perform well, the company seeks to streamline the relationship with Genentech by making the biotechnology leader a fully owned entity. By Steven Niles
Sanofi-Aventis Sanofi-Aventis’ growth is attributable to a regional approach to business operations, backed by a comprehensive product portfolio. By Gina-Louise Monari
Schering-Plough Falling Vytorin prescriptions, prompted by less-than-stellar clinical trial revelations, have made for a rocky 2008. By Gina-Louise Monari
Wyeth With new leadership, a new biotechnology focus, new productivity initiatives, and five new products, the ground is shifting rapidly at Wyeth. By Joshua Slatko
Reach an engaged audience with your brand's message
Download the Med Ad News, R&D Directions, and PharmaLive.com media kit
New
Special Report from PharmaLive.com!
Top 50 Pharmaceutical Companies and Their Pipelines 2008
Today's Health
Today's Health, America's #1 Educational Health Care Television Series, provides an exciting look at the latest innovations in medicine and Healthcare.
Subscribe Now and Save!
Get access to premium content, free PDF reports, and more!
Guide to Contract Research Services
The Guide to Contract Research Services contains in-depth profiles of quality providers of a variety of contract research services. Click here to view advertiser profiles.
The Trend Report
Guideline Inc. has teamed up with Med Ad News to provide the special supplement, Managed Care: Trends in a Slowing Economy
